Healthcare

Lexaria Reports Scheduled Completion of Dosing in GLP-1-H26-7 Study

Lexaria Bioscience has completed dosing and final participant visits in Human Pilot Study #7, with laboratory analysis and data review now pending.

Published:
Reading Time
3 min

Lexaria Bioscience Corp. (NASDAQ:LEXX) said on November 19, 2026 that dosing and final participant visits had been completed as scheduled in Human Pilot Study #7, identified as GLP-1-H26-7. The 5-week study is examining two oral DehydraTECH-semaglutide, or DHT-sema, formulations alongside Novo’s commercially available Wegovy® tablets.

#Study moves to analysis and review

With the final blood samples collected, the remaining work includes laboratory testing, quality-control procedures, a review of the study data and preparation of a report. Lexaria said study information will not be shared with third parties until the data has completed that review process. The company plans to issue further information after the review and quality-control work is finished.

#Three-arm design compares tablet and capsule formats

The study has three arms and is assessing safety, tolerability and pharmacokinetic properties. The Lexaria formulations contain SNAC and are being tested in both tablet and capsule forms, with the results compared against Wegovy® tablets.

Participants received the study products under fasted pre-dose conditions, which Lexaria said are similar to the advised administration criteria for Novo’s oral semaglutide products. The company selected the 5-week dosing period because it expects that duration to allow semaglutide concentrations in the study arms to reach steady-state levels, where drug input and natural elimination are balanced.

#New formulation features

GLP-1-H26-7 is the first Lexaria human study to assess an oral tablet DHT-sema formulation. Earlier DehydraTECH GLP-1 studies used capsule formulations. Lexaria said the tablet design incorporates certain physical characteristics associated with the SNAC-inclusive tablet delivery approach used in Novo’s Rybelsus® and Wegovy® products.

The study also represents the first time Lexaria’s DHT-sema tablet and capsule formulations containing SNAC are being assessed over a multi-dose, multi-week period in humans. Human Pilot Studies #1 and #2, designated GLP-1-H24-1 and GLP-1-H24-2, included SNAC but used single-dose designs and did not use tablets. Those studies were conducted in 2024 and 2025.

#Company background and study funding

Lexaria says its DehydraTECH™ platform is a patented formulation and processing technology intended for oral drug delivery. The company operates a licensed in-house research laboratory and says it has 70 patents granted, with additional patents pending worldwide. Lexaria said GLP-1-H26-7 is fully funded through existing corporate resources.

#Research limitations and risks

No results from GLP-1-H26-7 have been reported in the announcement. Lexaria said there is no assurance that the proposed uses, benefits or advantages of its patented and patent-pending technology will be realised. The company also identified risks related to regulation and regulatory approvals, scientific discovery, the patent process, possible adverse effects from testing or product use, and delays or cancellations affecting research and development.

The release stated that its claims had not been evaluated by the Food and Drug Administration. It also said Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

#Key Takeaways

  • Lexaria completed dosing and final participant visits in the 5-week GLP-1-H26-7 human study.
  • The three-arm study compares SNAC-inclusive DHT-sema tablet and capsule formulations with Wegovy® tablets.
  • The next stages are laboratory analysis, quality control, data review and reporting.
  • Lexaria has not yet released study results and says information will follow after the data review is complete.

Original source: Read original article

Frequently Asked Questions